Oral disease-modifying therapies for multiple sclerosis.
about
dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitisSphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 5 via c-Fos-dependent suppression of IFN-β amplification loop.Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.Dimethyl Fumarate: A Review in Relapsing-Remitting MS.Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.The future of multiple sclerosis treatments.Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis.Teriflunomide in multiple sclerosis: an update.Comparing costs of illness of multiple sclerosis in three different years: A population-based study.Activation of the astrocytic Nrf2/ARE system ameliorates the formation of demyelinating lesions in a multiple sclerosis animal model.Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.Persistence to oral disease-modifying therapies in multiple sclerosis patients.
P2860
Q36085336-C7022D53-B444-4BE8-AB77-6C71B639B539Q36299846-F05E4D9B-4182-41CF-9FD6-44FFC4D7ED5DQ36669117-0BC6DE5C-D0B2-4041-8CA7-1F50B0BA774EQ38649412-3659C803-C7B8-4C83-882C-2C5D29564D3BQ38675014-85FF1AC0-72E0-4605-A085-4BAD2569AD3BQ38802998-28BD791D-6B3F-4204-80A3-7A3BC89A2A5DQ38808485-0DC45AF0-AF43-455D-9DDE-B9A97B867B98Q38896543-084A637B-8BCE-4FF2-BCE3-9D4BDE5D2A8EQ39114065-D95B221A-E8B6-408A-9124-69CE954F9177Q47930580-9B22226F-DDF8-47E9-B022-B0C32C655CEDQ48472483-FABF6C99-155E-492B-901B-8BE4E59A6E5DQ50016769-59621A51-FCC3-49C6-BDD7-8A030B7110A1Q50498068-3D3EB075-9122-4A07-B643-72FCF26A1B72
P2860
Oral disease-modifying therapies for multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Oral disease-modifying therapies for multiple sclerosis.
@ast
Oral disease-modifying therapies for multiple sclerosis.
@en
Oral disease-modifying therapies for multiple sclerosis.
@nl
type
label
Oral disease-modifying therapies for multiple sclerosis.
@ast
Oral disease-modifying therapies for multiple sclerosis.
@en
Oral disease-modifying therapies for multiple sclerosis.
@nl
prefLabel
Oral disease-modifying therapies for multiple sclerosis.
@ast
Oral disease-modifying therapies for multiple sclerosis.
@en
Oral disease-modifying therapies for multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Oral disease-modifying therapies for multiple sclerosis.
@en
P2093
Ho Jin Kim
Manuella Edler Zandoná
Su-Hyun Kim
Woojun Kim
P2860
P356
10.3988/JCN.2015.11.1.9
P577
2015-01-02T00:00:00Z